Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
hydroxyethyl starch (voluven) (1 trial)
sodium chloride (1 trial)
pamrevlumab (1 trial)
Fibrosis (Phase 2)
Idiopathic Pulmonary Fibrosis (Phase 2)
Pulmonary Fibrosis (Phase 2)
Trials (2 total)
Trial APIs (3 total)